Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × imgatuzumab × Clear all

NCT01326000 2022-11-17

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms